Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has shared an update.
On February 23, 2026, OKYO Pharma announced that an abstract detailing the first-in-human study of its lead candidate urcosimod in neuropathic corneal pain has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver, to be held May 3–7, 2026. Chief Scientific Officer Raj Patil, Ph.D., will present Phase 2a proof-of-concept data showing clinically meaningful reductions in pain and quality-of-life improvements, with signals suggesting potential restoration of corneal nerve structure.
Neuropathic corneal pain is a chronic, debilitating ocular condition with no FDA-approved therapies, leaving patients reliant on off-label treatments that often provide limited benefit. Building on the positive Phase 2a NCP results and prior pain-reduction data in dry eye disease, OKYO plans to advance urcosimod into a larger, approximately 150-patient multicenter Phase 2b/3 trial in the coming months, a step that could strengthen its position in ophthalmology and potentially address a major unmet medical need if later-stage results are successful.
The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases. The company’s flagship product candidate is urcosimod, a novel, non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity, which has received FDA Fast Track designation for NCP and previously demonstrated efficacy in dry eye disease.
Average Trading Volume: 254,555
Technical Sentiment Signal: Sell
Current Market Cap: $71.78M
See more data about OKYO stock on TipRanks’ Stock Analysis page.